OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Ning Kang, Mark Eccleston, Pier‐Luc Clermont, et al.
Epigenomics (2020) Vol. 12, Iss. 16, pp. 1457-1476
Open Access | Times Cited: 53
Ning Kang, Mark Eccleston, Pier‐Luc Clermont, et al.
Epigenomics (2020) Vol. 12, Iss. 16, pp. 1457-1476
Open Access | Times Cited: 53
Showing 26-50 of 53 citing articles:
General transcription factor TAF4 antagonizes epigenetic silencing by Polycomb to maintain intestine stem cell functions
Susanna Säisä-Borreill, Guillaume Davidson, Thomas Kleiber, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 3, pp. 839-853
Open Access | Times Cited: 5
Susanna Säisä-Borreill, Guillaume Davidson, Thomas Kleiber, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 3, pp. 839-853
Open Access | Times Cited: 5
The epigenome and the many facets of cancer drug tolerance
Paul C. Moore, Kurt W. Henderson, Marie Classon
Advances in cancer research (2023), pp. 1-39
Closed Access | Times Cited: 5
Paul C. Moore, Kurt W. Henderson, Marie Classon
Advances in cancer research (2023), pp. 1-39
Closed Access | Times Cited: 5
Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus
Michelle Khattri, Yutaka Amako, Julia R. Gibbs, et al.
Tumour Virus Research (2023) Vol. 16, pp. 200264-200264
Open Access | Times Cited: 5
Michelle Khattri, Yutaka Amako, Julia R. Gibbs, et al.
Tumour Virus Research (2023) Vol. 16, pp. 200264-200264
Open Access | Times Cited: 5
Predictive Significance of Circulating Histones in Hepatocellular Carcinoma Patients Treated with Sorafenib
Francesca Salani, Maryam Latarani, Andrea Casadei‐Gardini, et al.
Epigenomics (2022) Vol. 14, Iss. 9, pp. 507-517
Open Access | Times Cited: 8
Francesca Salani, Maryam Latarani, Andrea Casadei‐Gardini, et al.
Epigenomics (2022) Vol. 14, Iss. 9, pp. 507-517
Open Access | Times Cited: 8
Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy
Asmita Parab, Lokesh Kumar Bhatt, Abdelwahab Omri
Biomedicines (2023) Vol. 11, Iss. 1, pp. 169-169
Open Access | Times Cited: 4
Asmita Parab, Lokesh Kumar Bhatt, Abdelwahab Omri
Biomedicines (2023) Vol. 11, Iss. 1, pp. 169-169
Open Access | Times Cited: 4
EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma
Shan Xu, Bohan Ma, Xiaoyu Feng, et al.
Translational Andrology and Urology (2023) Vol. 12, Iss. 1, pp. 71-82
Open Access | Times Cited: 4
Shan Xu, Bohan Ma, Xiaoyu Feng, et al.
Translational Andrology and Urology (2023) Vol. 12, Iss. 1, pp. 71-82
Open Access | Times Cited: 4
DNA Damage Repair Gene Mutations and Correlations with Immune Regulatory Gene Expression in Pancancer
Kanchana Yadav, Trishala Das, Andrew M. Lynn
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Kanchana Yadav, Trishala Das, Andrew M. Lynn
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Reversing EZH2‐Mediated Epigenetic Silence with Photodynamic Polymeric Nanoparticles for Synergistically Enhanced Antitumor Immunotherapy
Lei Cao, Dongsheng Tang, Zhen Yu, et al.
Advanced Functional Materials (2024)
Closed Access | Times Cited: 1
Lei Cao, Dongsheng Tang, Zhen Yu, et al.
Advanced Functional Materials (2024)
Closed Access | Times Cited: 1
Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential
Maria Saveria Gilardini Montani, Rossella Benedetti, Mara Cirone
Molecules (2024) Vol. 29, Iss. 24, pp. 5817-5817
Open Access | Times Cited: 1
Maria Saveria Gilardini Montani, Rossella Benedetti, Mara Cirone
Molecules (2024) Vol. 29, Iss. 24, pp. 5817-5817
Open Access | Times Cited: 1
Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs
Tomás Alarcón, Josep Sardanyés, Antoni Guillamon, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 6, pp. e1008408-e1008408
Open Access | Times Cited: 10
Tomás Alarcón, Josep Sardanyés, Antoni Guillamon, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 6, pp. e1008408-e1008408
Open Access | Times Cited: 10
Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
MHD Ouis Al Khatib, Giulia Pinton, Laura Moro, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1537-1537
Open Access | Times Cited: 3
MHD Ouis Al Khatib, Giulia Pinton, Laura Moro, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1537-1537
Open Access | Times Cited: 3
Less Severe Sepsis in Cecal Ligation and Puncture Models with and without Lipopolysaccharide in Mice with Conditional Ezh2-Deleted Macrophages (LysM-Cre System)
Pornpimol Phuengmaung, Phuriwat Khiewkamrop, Jiradej Makjaroen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8517-8517
Open Access | Times Cited: 3
Pornpimol Phuengmaung, Phuriwat Khiewkamrop, Jiradej Makjaroen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8517-8517
Open Access | Times Cited: 3
Epigenetic inhibitors and their role in cancer therapy
Nouha Abdelaziz, Lubna Therachiyil, Hana Q. Sadida, et al.
International review of cell and molecular biology (2023), pp. 211-251
Closed Access | Times Cited: 3
Nouha Abdelaziz, Lubna Therachiyil, Hana Q. Sadida, et al.
International review of cell and molecular biology (2023), pp. 211-251
Closed Access | Times Cited: 3
Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer
Min Gao, Li Y, Peijun Cao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Min Gao, Li Y, Peijun Cao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma
Jing Zeng, Lu Sun, Jiaming Huang, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 4
Jing Zeng, Lu Sun, Jiaming Huang, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 4
Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
Kui Fan, Chuanlong Zhang, Bohui Zhang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Kui Fan, Chuanlong Zhang, Bohui Zhang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 3
An unusual association of deletion of SMARCB1 in a patient with intracranial yolk sac tumor: A case-report
Ajinkya Gupte, Eman T. Al‐Antary, Katherine Regling, et al.
Pediatric Hematology Oncology Journal (2024) Vol. 9, Iss. 2, pp. 82-86
Open Access
Ajinkya Gupte, Eman T. Al‐Antary, Katherine Regling, et al.
Pediatric Hematology Oncology Journal (2024) Vol. 9, Iss. 2, pp. 82-86
Open Access
Relationship between EZH2 expression and prognosis of patients with hepatocellular carcinoma using a pathomics predictive model
Xulin Zhou, Muran Man, Min Cui, et al.
Heliyon (2024) Vol. 10, Iss. 20, pp. e38562-e38562
Open Access
Xulin Zhou, Muran Man, Min Cui, et al.
Heliyon (2024) Vol. 10, Iss. 20, pp. e38562-e38562
Open Access
Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review
Michael S. Wang, Jonathan H. Sussman, Jun-Jun Xu, et al.
Life (2024) Vol. 14, Iss. 12, pp. 1645-1645
Open Access
Michael S. Wang, Jonathan H. Sussman, Jun-Jun Xu, et al.
Life (2024) Vol. 14, Iss. 12, pp. 1645-1645
Open Access
Next frontier in cancer treatment: an iPSC supported CAR-T cell therapies
Tayyaba Sona
Asia-Pacific Journal of Oncology (2024)
Open Access
Tayyaba Sona
Asia-Pacific Journal of Oncology (2024)
Open Access
Inhibition of EZH2 Causes Retrotransposon Derepression and Immune Activation in Porcine Lung Alveolar Macrophages
Liangliang Zhang, Jian Jin, Weiyun Qin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2394-2394
Open Access | Times Cited: 1
Liangliang Zhang, Jian Jin, Weiyun Qin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2394-2394
Open Access | Times Cited: 1
Epigenetic therapies—update on lysine methyltransferase/PRC complex inhibitors
Sunkyu Kim, Natalie M. Barkey, Onur Atasoylu, et al.
Elsevier eBooks (2023), pp. 373-405
Closed Access | Times Cited: 1
Sunkyu Kim, Natalie M. Barkey, Onur Atasoylu, et al.
Elsevier eBooks (2023), pp. 373-405
Closed Access | Times Cited: 1
The Heightened Importance of EZH2 in Cancer Immunotherapy
Lin Xiaohu, Wenkai Zhou, Chengzhong Lin, et al.
Cancer Screening and Prevention (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 1
Lin Xiaohu, Wenkai Zhou, Chengzhong Lin, et al.
Cancer Screening and Prevention (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 1
Revealing Pan-Histology Immunomodulatory Targets in Pediatric Central Nervous System Tumors
Robert Galvin, Sampreeti Jena, Danielle Maeser, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5455-5455
Open Access | Times Cited: 1
Robert Galvin, Sampreeti Jena, Danielle Maeser, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5455-5455
Open Access | Times Cited: 1
Data from PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer
Juyeong Hong, Ji Hoon Lee, Zhao Zhang, et al.
(2023)
Open Access
Juyeong Hong, Ji Hoon Lee, Zhao Zhang, et al.
(2023)
Open Access
